减重药物奥利司他临床疗效与安全性的研究新进展  

New progress in research on the efficacy and safety of weight-loss drug orlistat

作　　者：覃萌 谭惠文[1] 余叶蓉[1,2] QIN Meng;TAN Huiwen;YU Yerong(Department of Endocrinology and Metabolism,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China;Laboratory of Endocrinolgy and Metabolism,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China)

机构地区：[1]四川大学华西医院内分泌代谢科,成都610041 [2]四川大学华西医院内分泌代谢研究室,成都610041

出　　处：《华西医学》2021年第9期1297-1302,共6页West China Medical Journal

基　　金：国家自然科学基金(81070675);四川省科学技术厅科技支撑计划项目(2016SZ0058)。

摘　　要：具有新型作用机理的奥利司他是目前国内唯一批准的口服减重药。奥利司他除了控制体质量之外,还能显著改善超重/肥胖患者的血糖、血压、脂代谢紊乱、脂联素以及胰岛素浓度等肥胖相关生化指标。最近,奥利司他被批准用于多囊卵巢综合征患者的体重控制。尽管有临床试验支持奥利司他具有良好的减重疗效,但其应用于肥胖相关疾病的远期安全性和有效性仍有待进一步确定。该文围绕其临床疗效与安全性的研究新进展作一简要综述,旨在为临床上该药的更合理应用提供一定参考。Orlistat,which has a new mechanism of action,is currently the only approved weight-loss drug in China.In addition to controlling body weight,orlistat can significantly improve blood glucose,blood pressure,dyslipidemia,adiponectin,insulin concentration and other obesity-related biochemical indicators in patients with overweight/obese.Recently,orlistat was approved for weight management in patients with polycystic ovary syndrome.Although there are clinical trials supporting the good weight loss efficacy of orlistat,its long-term safety and effectiveness in obesity-related diseases still need to be further determined.This article provides a brief review of the new progress in the clinical efficacy and safety of orlistat,aiming to provide a reference for the more rational drug application.

关 键 词：奥利司他 肥胖 超重 有效性 安全性 

分 类 号：R969.3[医药卫生—药理学]